Literature DB >> 28760208

Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis.

Akshay Bagai1, Karen P Alexander2, Jeffrey S Berger3, Roxy Senior4, Chakkanalil Sajeev5, Radoslaw Pracon6, Kreton Mavromatis7, Jose Luis Lopez-Sendón8, Gilbert Gosselin9, Ariel Diaz10, Gian Perna11, Jarozlaw Drozdz12, Dennis Humen13, Birute Petrauskiene14, Asim N Cheema15, Denis Phaneuf16, Subhash Banerjee17, Todd D Miller18, Sasko Kedev19, Herwig Schuchlenz20, Gregg W Stone21, Shaun G Goodman22, Kenneth W Mahaffey23, Allan S Jaffe18, Yves D Rosenberg24, Sripal Bangalore3, L Kristin Newby2, David J Maron23, Judith S Hochman3, Bernard R Chaitman25.   

Abstract

BACKGROUND: The Universal Definition of Myocardial Infarction recommends the 99th percentile concentration of cardiac troponin in a normal reference population as part of the decision threshold to diagnose type 1 spontaneous myocardial infarction. Adoption of this recommendation in contemporary worldwide practice is not well known.
METHODS: We performed a cohort study of 276 hospital laboratories in 31 countries participating in the National Heart, Lung, and Blood Institute-sponsored International Study of Comparative Health Effectiveness with Medical and Invasive Approaches trial. Each hospital laboratory's troponin assay manufacturer and model, the recommended assay's 99th percentile upper reference limit (URL) from the manufacturer's package insert, and the troponin concentration used locally as the decision level to diagnose myocardial infarction were ascertained.
RESULTS: Twenty-one unique troponin assays from 9 manufacturers were used by the surveyed hospital laboratories. The ratio of the troponin concentration used locally to diagnose myocardial infarction to the assay manufacturer-determined 99th percentile URL was <1 at 19 (6.6%) laboratories, equal to 1 at 91 (31.6%) laboratories, >1 to ≤5 at 101 (35.1%) laboratories, >5 to ≤10 at 34 (11.8%) laboratories, and >10 at 43 (14.9%) laboratories. The variability in troponin decision level for myocardial infarction relative to the assay 99th percentile URL was present for laboratories in and outside of the United States, as well as for high- and standard-sensitivity assays.
CONCLUSIONS: There is substantial hospital-level variation in the troponin threshold used to diagnose myocardial infarction; only one-third of hospital laboratories currently follow the Universal Definition of Myocardial Infarction consensus recommendation for use of troponin concentration at the 99th percentile of a normal reference population as the decision level to diagnose myocardial infarction. This variability across laboratories has important implications for both the diagnosis of myocardial infarction in clinical practice as well as adjudication of myocardial infarction in clinical trials.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28760208      PMCID: PMC5543710          DOI: 10.1016/j.ahj.2017.04.016

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

Review 1.  A comprehensive review of upper reference limits reported for (high-)sensitivity cardiac troponin assays: the challenges that lie ahead.

Authors:  Eline P M Cardinaels; Alma M A Mingels; Leo H J Jacobs; Steven J R Meex; Otto Bekers; Marja P van Dieijen-Visser
Journal:  Clin Chem Lab Med       Date:  2012-03-16       Impact factor: 3.694

2.  Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Authors:  Lars Wallentin; Daniel Lindholm; Agneta Siegbahn; Lisa Wernroth; Richard C Becker; Christopher P Cannon; Jan H Cornel; Anders Himmelmann; Evangelos Giannitsis; Robert A Harrington; Claes Held; Steen Husted; Hugo A Katus; Kenneth W Mahaffey; Ph Gabriel Steg; Robert F Storey; Stefan K James
Journal:  Circulation       Date:  2013-10-29       Impact factor: 29.690

3.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

Authors:  Karen A Hicks; James E Tcheng; Biykem Bozkurt; Bernard R Chaitman; Donald E Cutlip; Andrew Farb; Gregg C Fonarow; Jeffrey P Jacobs; Michael R Jaff; Judith H Lichtman; Marian C Limacher; Kenneth W Mahaffey; Roxana Mehran; Steven E Nissen; Eric E Smith; Shari L Targum
Journal:  Circulation       Date:  2014-12-29       Impact factor: 29.690

4.  How Well Do Laboratories Adhere to Recommended Clinical Guidelines for the Management of Myocardial Infarction: The CARdiac MArker Guidelines Uptake in Europe Study (CARMAGUE).

Authors:  Paul Collinson; Angelika Hammerer-Lercher; Janne Suvisaari; Fred S Apple; Rob H Christenson; Kari Pulkki; Marja P van Dieijen-Visser; Christopher J Duff; Hannsjörg Baum; Ana Stavljenic-Rukavina; Kristin M Aakre; Michel R Langlois; Sanja Stankovic; Paivi Laitinen
Journal:  Clin Chem       Date:  2016-07-26       Impact factor: 8.327

5.  Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome.

Authors:  Erin A Bohula May; Marc P Bonaca; Petr Jarolim; Elliott M Antman; Eugene Braunwald; Robert P Giugliano; L Kristin Newby; Marc S Sabatine; David A Morrow
Journal:  Clin Chem       Date:  2013-09-19       Impact factor: 8.327

6.  Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population.

Authors:  Fred S Apple; Ranka Ler; MaryAnn M Murakami
Journal:  Clin Chem       Date:  2012-09-14       Impact factor: 8.327

7.  Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients.

Authors:  Michael C Kontos; Rakesh Shah; Lucie M Fritz; F Philip Anderson; James L Tatum; Joseph P Ornato; Robert L Jesse
Journal:  J Am Coll Cardiol       Date:  2004-03-17       Impact factor: 24.094

8.  Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy.

Authors:  Evangelos Giannitsis; Lars Wallentin; Stefan K James; Maria Bertilsson; Agneta Siegbahn; Robert F Storey; Steen Husted; Christopher P Cannon; Paul W Armstrong; Philippe G Steg; Hugo A Katus
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2016-04-04

9.  Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study.

Authors:  Nicholas L Mills; Kuan Ken Lee; David A McAllister; Antonia M D Churchhouse; Margaret MacLeod; Mary Stoddart; Simon Walker; Martin A Denvir; Keith A A Fox; David E Newby
Journal:  BMJ       Date:  2012-03-15

10.  Misdiagnosis of Myocardial Infarction Related to Limitations of the Current Regulatory Approach to Define Clinical Decision Values for Cardiac Troponin.

Authors:  Karin Wildi; Maria Rubini Gimenez; Raphael Twerenbold; Tobias Reichlin; Cedric Jaeger; Amely Heinzelmann; Christiane Arnold; Berit Nelles; Sophie Druey; Philip Haaf; Petra Hillinger; Nicolas Schaerli; Philipp Kreutzinger; Yunus Tanglay; Thomas Herrmann; Zoraida Moreno Weidmann; Lian Krivoshei; Michael Freese; Claudia Stelzig; Christian Puelacher; Katharina Rentsch; Stefan Osswald; Christian Mueller
Journal:  Circulation       Date:  2015-05-06       Impact factor: 29.690

View more
  6 in total

Review 1.  Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future.

Authors:  Farah Omran; Ioannis Kyrou; Faizel Osman; Ven Gee Lim; Harpal Singh Randeva; Kamaljit Chatha
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

2.  Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.

Authors:  Bernard R Chaitman; Karen P Alexander; Derek D Cyr; Jeffrey S Berger; Harmony R Reynolds; Sripal Bangalore; William E Boden; Renato D Lopes; Marcin Demkow; Gian Piero Perna; Robert K Riezebos; Edward O McFalls; Subhash Banerjee; Akshay Bagai; Gilbert Gosselin; Sean M O'Brien; Frank W Rockhold; David D Waters; Kristian A Thygesen; Gregg W Stone; Harvey D White; David J Maron; Judith S Hochman
Journal:  Circulation       Date:  2020-12-03       Impact factor: 29.690

3.  High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.

Authors:  Anoop S V Shah; Atul Anand; Fiona E Strachan; Amy V Ferry; Kuan Ken Lee; Andrew R Chapman; Dennis Sandeman; Catherine L Stables; Philip D Adamson; Jack P M Andrews; Mohamed S Anwar; John Hung; Alistair J Moss; Rachel O'Brien; Colin Berry; Iain Findlay; Simon Walker; Anne Cruickshank; Alan Reid; Alasdair Gray; Paul O Collinson; Fred S Apple; David A McAllister; Donogh Maguire; Keith A A Fox; David E Newby; Christopher Tuck; Ronald Harkess; Richard A Parker; Catriona Keerie; Christopher J Weir; Nicholas L Mills
Journal:  Lancet       Date:  2018-08-28       Impact factor: 79.321

4.  Subclinical myocardial dysfunction in patients recovered from COVID-19.

Authors:  Leonardo Italia; Giacomo Ingallina; Antonio Napolano; Antonio Boccellino; Martina Belli; Francesco Cannata; Marco Rolando; Francesco Ancona; Francesco Melillo; Stefano Stella; Marco Ripa; Paolo Scarpellini; Moreno Tresoldi; Alessandro Ortalda; Beatrice Righetti; Francesco De Cobelli; Antonio Esposito; Fabio Ciceri; Antonella Castagna; Patrizia Querini Rovere; Gabriele Fragasso; Eustachio Agricola
Journal:  Echocardiography       Date:  2021-10-21       Impact factor: 1.724

5.  Universal Definition of Myocardial Infarction 99th Percentile versus Diagnostic Cut-off Value of Troponin I for Acute Coronary Syndromes.

Authors:  Antonio Haddad Tapias Filho; Gustavo Bernardes de Figueiredo Oliveira; João Italo Dias França; Rui Fernando Ramos
Journal:  Arq Bras Cardiol       Date:  2022-05-09       Impact factor: 2.667

6.  High sensitivity Troponin-T for prediction of adverse events in patients with COVID-19.

Authors:  Nikhil Singh; Rajeev K Anchan; Stephanie A Besser; Mark N Belkin; Mark D Cruz; Linda Lee; Dongbo Yu; Natasha Mehta; Ann B Nguyen; Francis J Alenghat
Journal:  Biomarkers       Date:  2020-11-24       Impact factor: 2.658

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.